Oncology

Cancer research lab
#Cancer research #Cancer Research UK #Clinical trial design #Oncology #Precision medicine

Cancer Research UK joins precision cancer medicine consortium

Cancer Research UK has joined the PRIME-ROSE project, a Europe-wide effort to boost patient access to precision cancer medicine (PCM). The PRIME-ROSE consortium consists of 24 partners, including nine beneficiaries and fifteen associated partners who will come together over the course of five years and work… Read More

#Cancer Research #News

T cells
#Antibodies #Cancer research #Immunotherapy #Oncology #T cell activation #Transcriptomics

Discovery could lead to more efficient cancer therapies

Scientists from Japan have identified regulator CD69, which controls the differentiation of CD8+ T cells within tumour-draining lymph nodes, thereby regulating anti-tumour immunity. Future cancer treatment based on antibodies against CD69 could enhance anti-tumour immune responses of CD8+ T cells and lead to more efficient cancer… Read More

#Cancer Research #News

Cancer Research Guide
#Cancer research #Drug development #Drug discovery #Guide #Oncology

DDW Cancer Research Guide 2023

Find out about the global breakthroughs, opportunities and developments in cancer research. Download the exclusive Guide and learn: Where the global breakthroughs, opportunities and developments are in cancer research Why cancer-associated proteins could be the Achilles’ heel of the disease… Read More

#DDW eBooks #DDW Guides

#Drug development #Drug discovery #Guide #Mouse models #Oncology #Preclinical investigations #TransCure bioServices

Unlock the full potential of your preclinical oncology studies

With an attrition rate of up to 95% for oncology drug development, it is evident that significant barriers still exist when it comes to translating preclinical investigation findings to in-human trials. This new Guide from TransCure bioServices explores how humanized mouse models can help accelerate the successful development… Read More

#News

#Drug development #Drug discovery #Guide #Mouse models #Oncology #Preclinical investigations

Unlock the full potential of your preclinical oncology studies with a humanized mouse model

With an attrition rate of up to 95% for oncology drug development, it is evident that significant barriers still exist when it comes to translating preclinical investigation findings to in-human trials. Our Guide explores how humanized mouse models can help accelerate the successful development of novel, safe, and effective treatments… Read More

#Intelligence #Resources

Genomics
#Europe #Genetics / genomics #Genomics #Immunotherapy #Oncology #Personalised medicine #The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Coalition will promote access to genomic profiling in Europe

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Exact Sciences, Guardant Health, Illumina, MSD and Novartis have come together to launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP). It is hoped that the Coalition will improve cancer care through increased routine clinical access and… Read More

#News

#AACR 2023 #Cancer research #DDW Events podcast #Meet the Researcher #Oncology #Surface Oncology

Meet the researcher: Vito Palombella, Surface Oncology 

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. Thomas speaks with Vito Palombella, Chief Scientific Officer at Surface Oncology.  MT: Where do… Read More

#Cancer Research #Exclusive Content #Opinion

#AACR 2023 #Cancer research #DDW Events podcast #Meet the Researcher #Oncology #Surface Oncology

Don’t miss AACR 2023 on the DDW Events podcast 

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, which took place in April 2023, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research, who you will hear from across three episodes of the… Read More

#Cancer Research #News #Opinion

Cancer cells
#American Society of Clinical Oncology #Breast cancer #Cancer research #HER2 #Oncology #The College of American Pathologists

Updates to HER2 testing guidelines reduces confusion 

The College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) have reaffirmed the Human Epidermal Growth Factor Receptor 2 (HER2) Breast Cancer Testing Guidelines, reducing confusion over terminology for reporting HER2 results.  The recent clinical trial for metastatic breast cancer patients (DESTINY-Breast04) found that… Read More

#Cancer Research #News #Regulatory #Trending News

Audience
#ASCO #Cancer research #Immutep #Oncology #Phase II trial

Immutep reports positive final data at ASCO 2023

Immutep revealed positive final data from Part C of the TACTI-002 Phase II trial at the ASCO 2023 Annual Meeting in Chicago, US. The trial evaluated eftilagimod alpha (efti), a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck) anti-PD-1 therapy Keytruda… Read More

#Cancer Research #News

Bladder
#ASCO #Cancer research #Clinical trial #Oncology #RemeGen

Promising results for disitamab vedotin in bladder cancer

RemeGen announced the latest clinical research results on disitamab vedotin (RC48) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers tested disitamab vedotin and toripalimab in combination on patients diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC). The objective of the study… Read More

#Cancer Research #News

Antibodies attack cancer cell
#ASCO #Cancer research #Clinical trials #Events #Oncology

Four breakthroughs in cancer research revealed at ASCO 2023

Ground-breaking data from several key cancer trials were announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ADAURA Phase III trial The trial assessed Tagrisso (osimertinib) as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated… Read More

#Cancer Research #News #Trending News

Chemistry
#Cancer research #Click chemistry #Johnson & Johnson #Oncology #Partnership #Shasqi

Partners will use click chemistry to create targeted cancer therapies

Biotech company Shasqi and Johnson & Johnson have entered into a research collaboration to develop new cancer therapies. Shasqi’s Click Activated Protodrugs Against Cancer (CAPAC) platform relies on chemistry for activation of drugs at the tumour. The platform is made up of a tumour-targeting agent and… Read More

#Cancer Research #News

Breast cancer
#ASCO #Breast cancer #Cancer research #Novartis #Oncology #Phase III trial

Drug reduced the risk of breast cancer recurrence by 25%

Positive primary endpoint data from Novartis’ pivotal Phase III NATALEE trial has been presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Data showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2%… Read More

#Cancer Research #News #Trending News

Laboratory research
#Antibody #ASCO #Cancer research #Clinical trials #Immunotherapy #Janssen #Oncology #T cell activation

Janssen updates ASCO 2023 on oncology pipeline

Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that… Read More

#Cancer Research #News #Trending News